Compare ICCC & PETS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ICCC | PETS |
|---|---|---|
| Founded | 1982 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail-Drug Stores and Proprietary Stores |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.8M | 61.6M |
| IPO Year | 1995 | 2003 |
| Metric | ICCC | PETS |
|---|---|---|
| Price | $10.02 | $2.13 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 28.0K | ★ 59.4K |
| Earning Date | 05-15-2026 | 06-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.85 | 18.92 |
| EPS | ★ 0.21 | N/A |
| Revenue | $26,493,169.00 | ★ $273,800,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 51.64 | N/A |
| 52 Week Low | $4.52 | $1.57 |
| 52 Week High | $10.25 | $4.32 |
| Indicator | ICCC | PETS |
|---|---|---|
| Relative Strength Index (RSI) | 73.69 | 34.63 |
| Support Level | $5.85 | N/A |
| Resistance Level | N/A | $2.44 |
| Average True Range (ATR) | 0.50 | 0.08 |
| MACD | 0.12 | -0.01 |
| Stochastic Oscillator | 97.37 | 6.21 |
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.